Compare AbCellera Biologics Inc (ABCL) vs Wayfair Inc (W) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Wayfair Inc — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while Wayfair Inc trades at $85.3 (market cap $12.31B). The key difference: Wayfair Inc is far larger — about 5.2× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | W | |
|---|---|---|
Market Cap | $2.35B | $12.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $119.05 |
52-Week Low | $2.78 | $53.37 |
Enterprise Value | $1.99B | $14.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Wayfair (W) trades at $93.18, down 1.4% today, with a bullish technical outlook supported by moving averages and positive momentum indicators. The company shows mixed fundamentals with strong revenue growth to $12.46B in 2025 but negative net income margins of -2.41%. Recent analyst upgrades to Strong Buy highlight optimism around earnings potential, though high debt levels and competitive pressures remain concerns.
Investment outlook balances strong analyst support (52% buy ratings) against fundamental challenges including negative profitability and elevated debt. The stock offers momentum potential with upcoming Q2 earnings on August 4, 2026 as a key catalyst, but requires careful monitoring of margin improvement and debt management for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
